Active	Status	Sponsor type	Region	Phase	Filter
8 Active 0 Inactive 8 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   - « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   Show only changed items Enrollment:

Advanced Filters

8 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Carmody, Stacey
NCT06427395: Open-Label Extension Study of Saroglitazar Magnesium in Participants With Primary Biliary Cholangitis	Recruiting	3	150	US, RoW	Saroglitazar Magnesium 1 mg	Zydus Therapeutics Inc.	Primary Biliary Cholangitis	04/27	07/27
PATENT-E, NCT05561114: Paclitaxel Coated Balloon for the Treatment of Chronic bEnigN sTricture- Esophagus	Recruiting	3	198	US	GIE Medical ProTractX3 TTS DCB, Control	GIE Medical	Esophageal Stricture	10/26	04/31
PATENT-B, NCT05561127: Paclitaxel Coated Balloon for the Treatment of Chronic bEnigN sTricture- Bowel	Recruiting	3	171	US	GIE Medical ProTractX3 TTS DCB, Control	GIE Medical	Bowel; Stricture	12/27	06/32
EPICS-III, NCT05133336 / 2022-001634-10: Saroglitazar Magnesium for Treatment of Primary Biliary Cholangitis	Completed	2/3	196	US, RoW	Saroglitazar Magnesium 1 mg, Saroglitazar Magnesium 2 mg, Placebo	Zydus Therapeutics Inc., Zydus Therapeutics Inc.	Primary Biliary Cholangitis	04/25	05/25
Emerson, DeShara
NCT06427395: Open-Label Extension Study of Saroglitazar Magnesium in Participants With Primary Biliary Cholangitis	Recruiting	3	150	US, RoW	Saroglitazar Magnesium 1 mg	Zydus Therapeutics Inc.	Primary Biliary Cholangitis	04/27	07/27
EPICS-III, NCT05133336 / 2022-001634-10: Saroglitazar Magnesium for Treatment of Primary Biliary Cholangitis	Completed	2/3	196	US, RoW	Saroglitazar Magnesium 1 mg, Saroglitazar Magnesium 2 mg, Placebo	Zydus Therapeutics Inc., Zydus Therapeutics Inc.	Primary Biliary Cholangitis	04/25	05/25
Hossain, Zakir
EPICS-III, NCT05133336 / 2022-001634-10: Saroglitazar Magnesium for Treatment of Primary Biliary Cholangitis	Completed	2/3	196	US, RoW	Saroglitazar Magnesium 1 mg, Saroglitazar Magnesium 2 mg, Placebo	Zydus Therapeutics Inc., Zydus Therapeutics Inc.	Primary Biliary Cholangitis	04/25	05/25
Albarouk, Sali
NCT06427395: Open-Label Extension Study of Saroglitazar Magnesium in Participants With Primary Biliary Cholangitis	Recruiting	3	150	US, RoW	Saroglitazar Magnesium 1 mg	Zydus Therapeutics Inc.	Primary Biliary Cholangitis	04/27	07/27

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Carmody, Stacey
NCT06427395: Open-Label Extension Study of Saroglitazar Magnesium in Participants With Primary Biliary Cholangitis	Recruiting	3	150	US, RoW	Saroglitazar Magnesium 1 mg	Zydus Therapeutics Inc.	Primary Biliary Cholangitis	04/27	07/27
PATENT-E, NCT05561114: Paclitaxel Coated Balloon for the Treatment of Chronic bEnigN sTricture- Esophagus	Recruiting	3	198	US	GIE Medical ProTractX3 TTS DCB, Control	GIE Medical	Esophageal Stricture	10/26	04/31
PATENT-B, NCT05561127: Paclitaxel Coated Balloon for the Treatment of Chronic bEnigN sTricture- Bowel	Recruiting	3	171	US	GIE Medical ProTractX3 TTS DCB, Control	GIE Medical	Bowel; Stricture	12/27	06/32
EPICS-III, NCT05133336 / 2022-001634-10: Saroglitazar Magnesium for Treatment of Primary Biliary Cholangitis	Completed	2/3	196	US, RoW	Saroglitazar Magnesium 1 mg, Saroglitazar Magnesium 2 mg, Placebo	Zydus Therapeutics Inc., Zydus Therapeutics Inc.	Primary Biliary Cholangitis	04/25	05/25
Emerson, DeShara
NCT06427395: Open-Label Extension Study of Saroglitazar Magnesium in Participants With Primary Biliary Cholangitis	Recruiting	3	150	US, RoW	Saroglitazar Magnesium 1 mg	Zydus Therapeutics Inc.	Primary Biliary Cholangitis	04/27	07/27
EPICS-III, NCT05133336 / 2022-001634-10: Saroglitazar Magnesium for Treatment of Primary Biliary Cholangitis	Completed	2/3	196	US, RoW	Saroglitazar Magnesium 1 mg, Saroglitazar Magnesium 2 mg, Placebo	Zydus Therapeutics Inc., Zydus Therapeutics Inc.	Primary Biliary Cholangitis	04/25	05/25
Hossain, Zakir
EPICS-III, NCT05133336 / 2022-001634-10: Saroglitazar Magnesium for Treatment of Primary Biliary Cholangitis	Completed	2/3	196	US, RoW	Saroglitazar Magnesium 1 mg, Saroglitazar Magnesium 2 mg, Placebo	Zydus Therapeutics Inc., Zydus Therapeutics Inc.	Primary Biliary Cholangitis	04/25	05/25
Albarouk, Sali
NCT06427395: Open-Label Extension Study of Saroglitazar Magnesium in Participants With Primary Biliary Cholangitis	Recruiting	3	150	US, RoW	Saroglitazar Magnesium 1 mg	Zydus Therapeutics Inc.	Primary Biliary Cholangitis	04/27	07/27